EZH2 and ovarian clear cell cancer: Although numerous studies have identified therapeutic vulnerabilities caused by ARID1A loss in ovarian clear cell carcinoma, including sensitivity to EZH2 inhibitors, Histone deacetylases (HDAC) inhibitors, and glutathione inhibitors (45–48), little is known about therapeutic selection conferred by ARID1A or AXIN1 loss in HCC.